Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Sun Pharmaceutical Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1885, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.64% on the day, quoting at 23948.45. The Sensex is at 76610.4, down 0.63%. Sun Pharmaceutical Industries Ltd has risen around 2.41% in last one month.
Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 1.62% in last one month and is currently quoting at 24762.9, up 1.26% on the day. The volume in the stock stood at 16.35 lakh shares today, compared to the daily average of 26.88 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1883.8, up 1.11% on the day. Sun Pharmaceutical Industries Ltd is up 13.44% in last one year as compared to a 4.38% drop in NIFTY and a 15.7% drop in the Nifty Pharma index.
The PE of the stock is 148.96 based on TTM earnings ending March 26.
Shares of Kaynes Technology India are banned from F&O trading on 22 June 2026.
Stocks to Watch:
Sun Pharmaceuticals Industries has entered into an agreement to acquire 100% stake in Innovcare Lifesciences, based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The total consideration of the transaction is valued at Rs 271.2 crore.
Garden Reach Shipbuilders & Engineers (GRSE) has been granted Navratna status by the Department of Public Enterprises (DPE) under the Ministry of Finance. The company said the recognition reflects its strong financial performance, operational efficiency and contribution to national security.
GE Power India announced a series of senior leadership changes, including the appointment of Rahul Rojal as Chief Financial Officer (CFO), as the company strengthens its management team amid ongoing business and project execution initiatives.
Goodluck India announced that its subsidiary, Goodluck Defence and Aerospace, has secured an order worth approximately Rs 255 crore for the supply of 155 mm long-range empty shells in ready-to-fill condition.
Zaggle Prepaid Ocean Services (Zaggle) announced that it has entered into an agreement with Punjab National Bank (PNB) to act as a co-branding partner for a retail credit card product. Under the agreement, Zaggle will leverage its existing corporate customer base to drive acquisition, marketing and promotion of the co-branded retail credit card. The partnership is aimed at expanding the reach of the co-branded card offering.
Texmaco Rail & Engineering has received a letter of intent (LoI) worth Rs 253.28 crore from JSW (South) Rail Logistics for the manufacture and supply of BFNSM1 rakes along with BVCM wagons. The domestic order is scheduled to be executed within 13.5 months from the effective date or commencement of work.
Innovcare Lifesciences is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The revenue from operations for FY 2025-26 was Rs 94.06 crore.
Sun Pharma stated that this acquisition is being done to strengthen product portfolio of the company.
The company expects to complete this transaction before 31 July 2026.
Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.
The company had reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026.
The scrip advanced 0.85% to currently trade at Rs 1852.70 on the BSE.
Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 23353.3. The Sensex is at 74101.32, down 0.33%.Sun Pharmaceutical Industries Ltd has eased around 2.56% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 2.59% in last one month and is currently quoting at 24086.6, up 0.38% on the day. The volume in the stock stood at 11.66 lakh shares today, compared to the daily average of 29.77 lakh shares in last one month.
The benchmark June futures contract for the stock is quoting at Rs 1793.9, down 0.5% on the day. Sun Pharmaceutical Industries Ltd jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.
The PE of the stock is 143.04 based on TTM earnings ending March 26.
For the full year,net profit rose 5.04% to Rs 11479.42 crore in the year ended March 2026 as against Rs 10929.04 crore during the previous year ended March 2025. Sales rose 11.87% to Rs 58220.11 crore in the year ended March 2026 as against Rs 52041.25 crore during the previous year ended March 2025.
Profit before tax (PBT) stood at Rs 3,551.34 crore in Q4 FY26, up 9.12% from Rs 3,254.35 crore posted in Q4 FY25.
India formulation sales rose 14.8% to Rs 4,835.9 crore during the quarter and accounted for 33.2% of total consolidated sales. For the full year FY26, India formulation sales grew 14% to Rs 19,290.4 crore.
The company said it maintained its position as India’s largest pharmaceutical company, with market share increasing from 8.1% to 8.4%, according to the Pharmarack MAT March 2026 report. Sun Pharma launched 11 new products during the quarter and 37 products during FY26.
US formulation sales stood at $459 million, down 1.1% YoY, as growth in innovative medicines offset weakness in the generics business. US sales accounted for approximately 28.8% of total consolidated sales. For the full year FY26, sales were $1,904 million.
Emerging Markets formulations sales were $306 million, up by 17.4% and accounted for 19.2% of total consolidated sales. For the full year FY26, sales were $1,265 million, growing 13.6%.
Formulation sales in Rest of World markets were $220 million, up by 10% and accounted for 13.8% of total consolidated sales. For the full year FY26, sales were $969 million, up 14.4%.
Global Innovative Medicines sales grew 20.1% YoY to $354 million in Q4 FY26 and accounted for 22.2% of total sales. For the full year FY26, innovative medicines sales rose 16.8% to $1,420 million.
External sales of active pharmaceutical ingredients (APIs) rose 26.4% to Rs 673.9 crore during the quarter. For the full year FY26, API sales were Rs. 21,853 million, up 2.6%.
Sun Pharmaceutical Industries said its R&D efforts continue to focus on both innovative and generic businesses, with ongoing investments aimed at strengthening its product pipeline across global markets. The company’s innovative R&D pipeline currently includes five novel entities in clinical stages. In the US market, Sun Pharma has approved ANDAs for 552 products, while 122 ANDA filings are awaiting US FDA approval, including 28 tentative approvals. During the quarter, the company filed seven ANDAs and received approvals for two. Sun Pharma also has a portfolio of 57 approved NDAs, while 13 NDAs are currently awaiting approval from the US FDA.
Kirti Ganorkar, Managing Director of the company, said, “Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition. Our U.S. Innovative Medicines business has surpassed USD 1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company.”
Meanwhile, the board has recommended a final dividend of Rs 5 per equity share of face value Re 1 each for FY26, subject to shareholders’ approval at the company’s 34th Annual General Meeting (AGM).
Shares of Sun Pharmaceutical slipped 2.43% to Rs 1,845.20 on the BSE.